AnderssonTB. Evolution of novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Basic Clin Pharmacol Toxicol, 2017:121; 234–238.
2.
EwartL, FabreK, ChakilamA, et al.Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Exp Biol Med (Maywood), 2017:242; 1579–1585.
3.
UnderhillGH, KhetaniSR. Bioengineered liver models for drug testing and cell differentiation studies. Cell Mol Gastroenterol Hepatol, 2018:5; 426–439.e421.
4.
TetsukaK, OhbuchiM, TabataK. Recent progress in hepatocyte culture models and their application to the assessment of drug metabolism, transport, and toxicity in drug discovery: The value of tissue engineering for the successful development of a microphysiological system. J Pharm Sci, 2017:106; 2302–2311.
5.
ProctorWR, FosterAJ, VogtJ, et al.Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol, 2017:91; 2849–2863.
6.
BellCC, DankersACA, LauschkeVM, et al.Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: A multicenter study. Toxicol Sci, 2018:162; 655–666.
7.
SimonM, Lisa FM. LV, et al. Transcriptomic, proteomic, and functional long-term characterization of multicellular three-dimensional human liver microtissues. Appl In Vitro Toxicol, 2018:4; 1–12.
8.
KermanizadehA, LohrM, RoursgaardM, et al.Hepatic toxicology following single and multiple exposure of engineered nanomaterials utilising a novel primary human 3D liver microtissue model. Part Fibre Toxicol, 2014:11; 56.
9.
LiL, ZhouQ, VossTC, et al.High-throughput imaging: Focusing in on drug discovery in 3D. Methods, 2016:96; 97–102.
10.
BazeA, ParmentierC, HendriksDFG, et al.3D-spheroid primary human hepatocytes in mono- and co-culture with non-parenchymal cells. Tissue Eng Part C Methods, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEC.2018.0134.
11.
MessnerS, AgarkovaI, MoritzW, et al.Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol, 2013:87; 209–213.
12.
HendriksDFG, Fredriksson PuigvertL, MessnerS, et al.Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability. Sci Rep, 2016:6; 35434.
13.
MeierF, FreyerN, BrzeszczynskaJ, et al.Hepatic differentiation of human iPSCs in different 3D models: A comparative study. Int J Mol Med, 2017:40; 1759–1771.
14.
StarokozhkoV, HemmingsenM, LarsenL, et al.Differentiation of human-induced pluripotent stem cell under flow conditions to mature hepatocytes for liver tissue engineering. J Tissue Eng Regen Med, 2018:12; 1273–1284.
15.
KouiY, KidoT, ItoT, et al.An in vitro human liver model by iPSC-derived parenchymal and non-parenchymal cells. Stem Cell Reports, 2017:9; 490–498.
16.
HannounZ, SteichenC, DianatN, et al.The potential of induced pluripotent stem cell derived hepatocytes. J Hepatol, 2016:65; 182–199.
17.
KimJH, WangM, LeeJ, et al.Prediction of hepatotoxicity for drugs using human pluripotent stem cell-derived hepatocytes. Cell Biol Toxicol, 2018:34; 51–64.
18.
LiuJT, LamprechtMP, DuncanSA. Using human induced pluripotent stem cell-derived hepatocyte-like cells for drug discovery. J Vis Exp, 2018 [Epub ahead of print]; DOI: 10.3791/57194.
19.
DavidsonMD, WareBR, KhetaniSR. Stem cell-derived liver cells for drug testing and disease modeling. Discov Med, 2015:19; 349–358.
20.
ZhangRR, TakebeT, MiyazakiL, et al.Efficient hepatic differentiation of human induced pluripotent stem cells in a three-dimensional microscale culture. Methods Mol Biol, 2014:1210; 131–141.
21.
ZhangRR, KoidoM, TadokoroT, et al.Human iPSC-derived posterior gut progenitors are expandable and capable of forming gut and liver organoids. Stem Cell Reports, 2018:10; 780–793.
22.
LiJ, XingF, ChenF, et al.Functional 3D human liver bud assembled from MSC-derived multiple liver cell lineages. Cell Transplant, 2018:963689718780332.
23.
BeckwittCH, ClarkAM, WheelerS, et al.Liver ‘organ on a chip’. Exp Cell Res, 2018:363; 15–25.
24.
LiX, GeorgeSM, VernettiL, et al.A glass-based, continuously zonated and vascularized human liver acinus microphysiological system (vLAMPS) designed for experimental modeling of diseases and ADME/TOX. Lab Chip, 2018:18; 2614–2631.
25.
RoweC, ShaeriM, LargeE, et al.Perfused human hepatocyte microtissues identify reactive metabolite-forming and mitochondria-perturbing hepatotoxins. Toxicol In Vitro, 2018:46; 29–38.
26.
EwartL, DehneEM, FabreK, et al.Application of microphysiological systems to enhance safety assessment in drug discovery. Annu Rev Pharmacol Toxicol, 2018:58; 65–82.
27.
OngLJY, IslamA, DasGuptaR, et al.A 3D printed microfluidic perfusion device for multicellular spheroid cultures. Biofabrication, 2017:9; 045005.
28.
LiAP. Evaluation of adverse drug properties with cryopreserved human hepatocytes and the integrated discrete multiple organ co-culture (IdMOC(TM)) system. Toxicol Res, 2015:31; 137–149.
29.
YangK, GuoC, WoodheadJL, et al.Sandwich-cultured hepatocytes as a tool to study drug disposition and drug-induced liver injury. J Pharm Sci, 2016:105; 443–459.
FDA Signs Collaborative Agreement with Emulate, Inc. to Use Organs-on-Chips Technology as a Toxicology Testing Platform for Understanding How Products Affect Human Health and Safety. Press Release, Emulate, Inc. April 11, 2017. https://emulatebio.com/press/fda-collab-agreement-emulate (Last accessed August17, 2018).
